CLEARWATER, Fla.--(BUSINESS WIRE)--Jan. 14, 2000
NVID
International, Inc. (OTC BB:NVID) announced today that it has closed
the definitive agreements for Axenohl(TM) and the Reservoir Metering
System ("RMS") with Innovative Medical Services (NASDAQ:PURE) of El
Cajon, California. The disinfection foundation of Axenohl(TM) and RMS
are derived from a form of silver and / or silver compounds, which
controls over 650 different microbes as cited by the National Academy
of Sciences.
The Axenohl(TM) and RMS agreements grant Innovative Medical
Services specific marketing and licensing rights for Axenohl(TM) and
the RMS silver ionization technology. NVID has received up-front
licensing fees for both Axenohl(TM) and RMS, and will receive
royalties on all Axenohl(TM) and RMS sales generated by Innovative
Medical Services per previous press releases.
Axenohl(TM) is NVID's patent-pending, non-toxic aqueous
disinfectant that poses no toxicity to humans or animals. Based upon
proprietary ionization stabilization technology, Axenohl(TM) does not
include the use of traditional disinfectants such as quaternary
ammonium salts, phenols, glutaraldehyde, chlorine or bromine
compounds. The technology enhances the disinfection properties of
halogens (chlorine) at reduced levels and is positioned to be a cost
effective, stand alone alternative to halogens in many markets where
conventional disinfection methodologies are being employed. The
disinfection efficacy of Axenohl(TM) has been well documented by
independent testing laboratories. Axenohl(TM) eliminates the following
test organism strains all within one minute and 99.9999% efficacy
(complete kill): Pseudomonas aeruginosa ATCC 15422, Staphylococcus
aureus ATCC 6538, Salmonella cholerasuis ATCC 10708, E. Coli ATCC
0157:H7, Listeria monocytogenes ATCC 11543, Entrococcus facium ATCC
11543, Rhinovirus (common colds) Rotavirus, (infectious diarrhea). The
Axenohl(TM) International Patent Application was published by the
World Intellectual Property Organization on April 22, 1999 under
publication Number WO 99/18790 and is available for public inspection.
A multi-year licensing arrangement for Axenohl(TM) is in place
with Innovative Medical Services for the following markets:
1. Healthcare Market
2. Point-of-Use / Point-of-Entry Market
3. Food Processing Market
4. Dental Water Lines
Innovative Medical Services is committed to two world-class
Axenohl(TM) research projects that include: The U.S. Department of
Agriculture's (Agricultural Research Service / Athens, GA) has signed
a Trust Fund Cooperative Agreement (Agreement No. 58-6612-0-203), and
has committed research dollars for one year specifically to evaluate
and identify Axenohl's efficacy and applications for food processing
(poultry) disinfection issues. This research project fits the goals of
the USDA, which is committed to evaluate disinfection technologies
that promise to be more efficacious, cost-effective and
environmentally friendly than traditional disinfectants.
Dr. Richard I. Karpay DDS, MPH and Chairman of the American
Dental Association ("ADA") subcommittee on air and water lines will
conduct approximately four months of research to evaluate the
disinfection effectiveness of Axenohl(TM) for dental unit waterlines.
The ADA recently has set new goals for dental waterlines, which state
that acceptable biologic quality of the water should be less than 200
CFU/mL. The State of California has taken the lead and already adopted
the less than 200 CFU/mL guideline established by the ADA. Both
research projects are projected to commence in February 2000.
Additional research just completed in November by EPL
Bio-Analytical Services of Harristown, IL and Key Laboratory Services
of Decatur, IL proves the disinfection efficacy of Axenohl(TM) against
Vancomycin Resistant Enterococcus ("VRE"). VRE is an Enteroccocus
organism that has become resistant to typical antibiotics frequently
used in hospitals. VRE is usually spread by direct contact with hands,
environmental surfaces or medical equipment that has been
contaminated. Axenohl(TM) was 99.9999 effective against VRE within one
minute at the low level of 1.18 ppm. The results of this research have
been submitted to the FDA as part of a broader submittal package that
seeks FDA compliance on 14 products for both human and veterinary
usage.
In addition, EPL Bio-Analytical has submitted the Axenohl(TM)
research data package for EPA registration purposes within the last
sixty days. NVID is optimistic that an EPA registration number for
Axenohl(TM) will be granted within the second quarter of 2000, if not
sooner.
The RMS ionization system is a non-halogen (chlorine)
disinfection system that effectively treats large volumes of water
with ionic silver. Designed to be a cost effective alternative to the
use of halogens for water disinfection in either single pass or
re-circulating systems, RMS technology delivers ionic silver using
proprietary assayed electrodes. The ions are metered into the process
water by dosing pumps based upon flow rates to ensure a precise dosage
of ions. Generation of the ion concentrate is produced off-line by the
RMS without utilizing the process water, enabling the equipment to
produce ions more effectively and efficiently than conventional
ionization systems. NVID was granted approval by the Director General
of Environmental Health for residential and commercial drinking water
disinfection in Mexico in December of 1998. An RMS system was
installed in Punta Mita, Mexico for disinfecting municipal drinking
water in October of 1999, in which NVID has been working with one of
the largest company's in Mexico City on this installation to evaluate
the technology for future projects.
About Innovative Medical Services
Innovative Medical Services, based in El Cajon, California,
manufactures and markets water purification, measuring, and dispensing
equipment used in pharmacies to reconstitute oral antibiotic
suspensions, and residential drinking water filtration systems used in
consumer markets. The Company's customer base for its Fillmaster(R)
pharmacy systems includes Wal-Mart, Walgreen's, American Stores,
Eckerd, Kroger, Fred Meyer, Target and CVS. The Company's Nutripure(R)
line of residential water systems includes a residential reverse
osmosis water system available as either a convenient, compact unit
easily installed beneath the sink, or as an attractive countertop
appliance requiring no installation. Brand recognition for the
Nutripure products is driven by the new Nutripure 2000 countertop
water filtration system. Nutripure 2000 competes with PUR(R), Brita(R)
and Culligan(R) products. The Company's products can be purchased
online form IMS' Yahoo(R) Store at stores.yahoo.com/nutripure or from
its web site at www.imspure.com.
About NVID International
NVID International, Inc. based in Clearwater, Florida
manufactures and markets patent and patent-pending, proprietary
ionization disinfection technologies that substantially reduce or
replace traditional disinfectants such as chlorine, quaternary
ammonium salts, phenols and glutaradehyde. Axenohl(TM) is NVID's
non-toxic disinfectant that is based upon ionization stabilization
technology that poses no toxicity to humans or mammals. Target markets
include: hospital water systems, POU / POE commercial, municipal, and
residential drinking water, FDA compliant consumer products for human
and veterinary usage, pools and spas, cisterns / wells, horticulture,
and food processing applications.
Except for historical information contained herein, the matters
discussed in this news release are forward-looking statements with
respect to the future activities of the Company. These forward-looking
statements by their vary nature involve risks and uncertainties and
represent the Company's judgement as of the date of this release. NVID
International, Inc. and Aqua Bio Technologies, Inc. can be reached at:
--30--fap/ny*
CONTACT: NVID International, Corporate Office
David Larson, 727/669-5005
dLarson@aquabiotech.com
or
Sales Office, 941/312-9100
aquabiotech@home.com
|
